SCHEMBL2799443

SCHEMBL2799443

COC(=O)c1c(C=[N+]([O-])C(C)(C)C)cc(OC)cc1OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.39
USP2 O75604 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ABCG2 Q9UNQ0 2/20 0.39
HPGD P15428 1/20 0.38
TXNRD1 Q16881 1/20 0.38
TXNRD3 Q86VQ6 1/20 0.38
TXNRD2 Q9NNW7 1/20 0.38
PTGS2 P35354 1/20 0.37
KMT2A Q03164 1/20 0.36
POLK Q9UBT6 1/20 0.36
POLH Q9Y253 1/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8293064 1.00 CYP3A4 (0.39) CYP3A4USP2MAPK1SMN1; SMN2ABCG2
SCHEMBL8292431 0.88 CYP3A4 (0.40) CYP3A4USP2MAPK1SMN1; SMN2ABCG2
SCHEMBL2798306 0.88 CYP3A4 (0.40) CYP3A4USP2MAPK1SMN1; SMN2ABCG2
SCHEMBL8294819 0.78 PTGS2 (0.40) CYP3A4USP2MAPK1SMN1; SMN2ABCG2
SCHEMBL2797430 0.78 PTGS2 (0.40) CYP3A4USP2MAPK1SMN1; SMN2ABCG2
SCHEMBL2801743 0.77 ALDH1A1 (0.50) CYP3A4USP2MAPK1SMN1; SMN2ABCG2
SCHEMBL2800212 0.77 PTPN1 (0.44) CYP3A4SMN1; SMN2ABCG2TXNRD1TXNRD3
SCHEMBL8293541 0.77 PTPN1 (0.44) CYP3A4SMN1; SMN2ABCG2TXNRD1TXNRD3
Methyl 2,4,6-Trimethoxybenzoate SCHEMBL2563067 0.74 CYP3A4 (0.58) CYP3A4USP2MAPK1SMN1; SMN2ABCG2
SCHEMBL14390324 0.73 CYP3A4 (0.41) CYP3A4USP2MAPK1SMN1; SMN2ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100168112-A1 2-Substituted and 4-substituted aryl nitrone compounds RENOVIS, INC. 2010-07-01 US disclosed
US-20070275932-A1 Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders RENOVIS, INC. 2007-11-29 US disclosed
US-20050182060-A1 2-Substituted and 4-substituted aryl nitrone compounds RENOVIS, INC. 2005-08-18 US disclosed
US-20050059638-A1 Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders RENOVIS, INC. 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275932-A1 Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders AHR, NAT1, ARNT CYP3A4 98/4885USP2 2941/4885MAPK1 2496/4885
US-20050059638-A1 Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders AHR, NAT1, ARNT CYP3A4 98/4885USP2 2941/4885MAPK1 2496/4885
US-20100168112-A1 2-Substituted and 4-substituted aryl nitrone compounds CXCR2, CCL5, CCL2 CYP3A4 1169/4885USP2 3411/4885MAPK1 1320/4885
US-20050182060-A1 2-Substituted and 4-substituted aryl nitrone compounds CXCR2, CCL5, CCL2 CYP3A4 1169/4885USP2 3411/4885MAPK1 1320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.